stoxline Quote Chart Rank Option Currency Glossary
AbbVie Inc. (ABBV)
143.41  1.02 (0.72%)    12-01 16:00
Open: 142.54
High: 144.1
Volume: 4,658,045
Pre. Close: 142.39
Low: 142.2801
Market Cap: 253,196(M)
Technical analysis
2023-12-01 4:17:59 PM
Short term     
Mid term     
Targets 6-month :  170.18 1-year :  198.78
Resists First :  145.71 Second :  170.18
Pivot price 139
Supports First :  139.61 Second :  135.85
MAs MA(5) :  140.29 MA(20) :  139.49
MA(100) :  145.97 MA(250) :  148.87
MACD MACD :  -0.9 Signal :  -1.7
%K %D K(14,3) :  73.2 D(3) :  52.9
RSI RSI(14): 58.9
52-week High :  168.11 Low :  130.96
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ABBV ] has closed Bollinger Bands are 33.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 142.88 - 143.41 143.41 - 143.83
Low: 136.59 - 137.25 137.25 - 137.79
Close: 141.38 - 142.42 142.42 - 143.25
Company Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Headline News

Sun, 03 Dec 2023
AbbVie: 4 Hidden Keys Investors Must Know To Judge ImmunoGen Acquisition (NYSE:ABBV) - Seeking Alpha

Fri, 01 Dec 2023
AbbVie: $10 Billion Cancer Deal To Boost Growth (NYSE:ABBV) - Seeking Alpha

Fri, 01 Dec 2023
AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion - Yahoo Finance

Thu, 30 Nov 2023
AbbVie Stock (NYSE:ABBV): Bet on a Smart Drugmaker and Dealmaker - - TipRanks

Thu, 30 Nov 2023
AbbVie Stock (NYSE:ABBV): Bet on a Smart Drugmaker and ... - Yahoo Finance

Thu, 30 Nov 2023
Why Abbvie Stock Popped Today - The Motley Fool

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers—General
Shares Out 1,770 (M)
Shares Float 1,760 (M)
Held by Insiders 0.1 (%)
Held by Institutions 71.4 (%)
Shares Short 13,230 (K)
Shares Short P.Month 12,310 (K)
Stock Financials
EPS 3.65
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.84
Profit Margin 11.8 %
Operating Margin 17.7 %
Return on Assets (ttm) 8.6 %
Return on Equity (ttm) 46.3 %
Qtrly Rev. Growth -6 %
Gross Profit (p.s.) 23.46
Sales Per Share 31.15
EBITDA (p.s.) 15.81
Qtrly Earnings Growth -54.8 %
Operating Cash Flow 25,510 (M)
Levered Free Cash Flow 24,070 (M)
Stock Valuations
PE Ratio 39.28
PEG Ratio -3
Price to Book value 20.93
Price to Sales 4.6
Price to Cash Flow 9.94
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android